We are live on !
Find out more
PFM Health Sciences Portfolio holdings
AUM
$1.17B
Turnover
44.83%
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter Est. Return
+32.88%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$1.17B
AUM Growth
+$68.7M
(+6.3%)
Cap. Flow
+$9.42M
Cap. Flow % of AUM
Cap. Flow %
0.81%
Top 10 Holdings %
Top 10 Hldgs %
33.9%
Holding
116
New
34
Increased
23
Reduced
41
Closed
18
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
1
year
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$26.9M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$19M |
| 3 |
Mettler-Toledo International
MTD
|
+$16.1M |
| 4 |
Merck
MRK
|
+$14.9M |
| 5 |
Cytokinetics
CYTK
|
+$13.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$50M |
| 2 |
Eli Lilly
LLY
|
+$27.1M |
| 3 |
Penumbra
PEN
|
+$25.8M |
| 4 |
Glaukos
GKOS
|
+$23.2M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.83% |
| 2 | Miscellaneous | 1.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
CALL
Cencora
COR
$66.7B
| $7.95M | 0.68% |
+28,100
| New | +$8.1M |
2026 Q2
0 quarters
|
|
52
iRhythm Holdings
IRTC
$3.1B
| $7.76M | 0.67% |
+65,196
| New | +$7.58M |
2026 Q2
0 quarters
|
|
53
Kodiak Sciences
KOD
$6.8B
| $7.53M | 0.65% |
193,315
+78,596
| +69% | +$3.06M |
2026 Q1
1 quarter
|
|
54
Abbott
ABT
$186B
| $7.46M | 0.64% |
82,230
-58,202
| -41% | -$5.31M |
2026 Q1
1 quarter
|
|
55
West Pharmaceutical
WST
$28.7B
| $7.44M | 0.64% |
+20,733
| New | +$6.34M |
2026 Q2
0 quarters
|
|
56
Takeda Pharmaceutical
TAK
$67.5B
| $7.12M | 0.61% |
+444,173
| New | +$7.35M |
2026 Q2
0 quarters
|
|
57
Hinge Health
HNGE
$9.8B
| $6.88M | 0.59% |
+82,860
| New | +$4.5M |
2026 Q2
0 quarters
|
|
58
Arcutis Biotherapeutics
ARQT
$3.48B
| $6.35M | 0.54% |
+242,069
| New | +$5.64M |
2026 Q2
0 quarters
|
|
59
Integra LifeSciences
IART
$1.12B
| $6.26M | 0.54% |
+348,746
| New | +$4.88M |
2026 Q2
0 quarters
|
|
60
Illumina
ILMN
$31.7B
| $6.16M | 0.53% |
35,040
+6,171
| +21% | +$903K |
2026 Q1
1 quarter
|
|
61
MeiraGTx Holdings
MGTX
$844M
| $6.15M | 0.53% |
+455,286
| New | +$4.52M |
2026 Q2
0 quarters
|
|
62
Oculis Holding
OCS
$418M
| $6.05M | 0.52% |
+436,042
| New | +$9.9M |
2026 Q2
0 quarters
|
|
63
Natera
NTRA
$46.8B
| $5.99M | 0.51% |
22,077
-37,927
| -63% | -$8.09M |
2026 Q1
1 quarter
|
|
64
Abivax
ABVX
$7.9B
| $5.77M | 0.49% |
43,264
+16,600
| +62% | +$1.88M |
2025 Q4
2 quarters
|
|
65
PUT
Centene
CNC
$34.8B
| $5.66M | 0.49% |
+88,200
| New | +$4.72M |
2026 Q2
0 quarters
|
|
66
Guardant Health
GH
$21B
| $5.51M | 0.47% |
+36,701
| New | +$3.99M |
2026 Q2
0 quarters
|
|
67
Celcuity
CELC
$3.14B
| $5.46M | 0.47% |
+52,155
| New | +$6.02M |
2026 Q2
0 quarters
|
|
68
Belite Bio
BLTE
$6.84B
| $5.36M | 0.46% |
34,803
-24,629
| -41% | -$3.77M |
2025 Q4
2 quarters
|
|
69
Structure Therapeutics
GPCR
$1.41B
| $4.91M | 0.42% |
91,550
-34,833
| -28% | -$1.54M |
2025 Q1
5 quarters
|
|
70
Arcus Biosciences
RCUS
$2.56B
| $4.69M | 0.4% |
+152,129
| New | +$3.76M |
2026 Q2
0 quarters
|
|
71
Charles River Laboratories
CRL
$16.3B
| $4.25M | 0.36% |
+18,747
| New | +$3.34M |
2026 Q2
0 quarters
|
|
72
Elanco Animal Health
ELAN
$13.2B
| $4.24M | 0.36% |
+172,489
| New | +$3.99M |
2026 Q2
0 quarters
|
|
73
argenx
ARGX
$61.7B
| $4.16M | 0.36% |
4,482
-53
| -1% | -$43.7K |
2022 Q2
16 quarters
|
|
74
Bio-Rad Laboratories Class A
BIO
$10B
| $4.11M | 0.35% |
+13,995
| New | +$3.97M |
2026 Q2
0 quarters
|
|
75
Spyre Therapeutics
SYRE
$9.8B
| $4.1M | 0.35% |
+46,217
| New | +$3.37M |
2026 Q2
0 quarters
|
|
Similar funds
PFM Health Sciences's Q2 2026 Portfolio in Review
As of Q2 2026, PFM Health Sciences held 116 positions worth $1.17B, up 6.3% from $1.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
PFM Health Sciences's Q2 2026 filing shows 34 new, 23 increased, 41 reduced and 18 closed positions. Its largest new stake was Humana: 94,375 shares worth $37.5M. The largest sale was Tenet Healthcare, an estimated $50M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 85% a quarter earlier, followed by Miscellaneous.
- PFM Health Sciences's largest Q2 2026 buy was Humana: 94,375 shares worth $37.5M.
- PFM Health Sciences added most to Ascendis Pharma A/S in Q2 2026, an estimated $19M increase.
- PFM Health Sciences's biggest Q2 2026 reduction was Tenet Healthcare, cutting an estimated $50M.
- PFM Health Sciences fully exited Glaukos in Q2 2026, selling an estimated $23.2M.
- PFM Health Sciences's ten largest holdings make up 34% of its $1.17B portfolio in Q2 2026.
- PFM Health Sciences opened 34 new positions and closed 18 in Q2 2026.
- PFM Health Sciences's portfolio value rose 6.3% quarter-over-quarter to $1.17B.
Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.